# Zacks

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/zacks-company
Canonical HTML page: https://getbiobrief.com/entity/zacks-company

## Recent coverage (2 stories)

### I-Mab Posts $(0.16) EPS; $9 PT Implies 371% Upside
2026-08-22 07:00:16 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

I-Mab, a clinical-stage oncology and immunology biotech, reported a $(0.16) quarterly EPS on Aug 20. With shares at $1.91, H.C. Wainwright's reiterated $9 target implies massive upside, though Weiss remains bearish. Institutional ownership sits at 38.38%.
Full story: https://getbiobrief.com/story/imab-nbp-q3-2026-earnings-biotech-analysis

### Aligos Therapeutics Beats Q2 Consensus by $0.95 EPS, Signaling Clinical Momentum
2026-08-09 17:05:04 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Aligos Therapeutics (ALGS) handily beat Q2 consensus earnings per share by $0.95, a significant outperformance for the clinical-stage biotech. This beat may reflect operational efficiencies, milestone payments, or clinical progress in its liver disease pipeline. Investors in the biotech space should watch for full financial disclosures to gauge the sustainability of this positive surprise.
Full story: https://getbiobrief.com/story/aligos-earnings-beat-0-95-eps

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.